Validation of the IMPEDE VTE score for prediction of venous thromboembolism in Chinese patients with multiple myeloma: A single-center retrospective cohort study

The Risk of Venous Thromboembolism and Ischemic Stroke Stratified by VTE Risk Following Multiple Myeloma: A Korean Population-Based Cohort Study

“…In France, the score was evaluated for 190 patients with NDMM registered in the MELISSE database, and the incidence of VTE in the low-, intermediate-, and high-risk groups was 5.9%, 9.4%, and 16.7%, respectively [26]. U.S.-and China-based chart review studies reported VTE incidences of 5.0%, 12.6%, and 24.1% and 3.8%, 8.6%, and 40.5% for the respective risk groups, underscoring the effectiveness of the IMPEDE score in VTE risk prediction [6,7]. Our study also estimated the VTE incidence to be 8.6% for the high-risk group with an IMPEDE VTE score ≥ 8 and 5.6% for those with a score < 8, showing a consistent pattern of increased risk with a higher score.…”

“…Unlike the SAVED score, which is designed for patients beginning iMiD induction therapy, the IMPEDE VTE score can be used for any MM-directed therapy [25]. To date, it has been evaluated in real-world studies from various countries, including the U.S., China, France, and Brazil, demonstrating superior VTE risk prediction capabilities to previous risk stratification models [6,7,26,27]. However, previous research has been confined to either single-or multicenter studies involving a limited number of patients, and studies at the population level are notably insufficient.…”

“…This model offers a structured approach for risk stratification by assigning weights to various VTE risk factors, thereby aiding in the initiation of chemotherapy for patients with MM. Its efficacy in predicting the VTE risk within a six-month timeframe has been validated in extensive cohort studies of American and Chinese populations [6,7].…”